NAS-150 is under clinical development by New Amsterdam Sciences and currently in Phase I for Progressive Supranuclear Palsy. According to GlobalData, Phase I drugs for Progressive Supranuclear Palsy does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the NAS-150 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NAS-150 overview
NAS-150 (AEOL-10150) is under development for the treatment of idiopathic pulmonary fibrosis, gastrointestinal and lung acute radiation syndrome, progressive supranuclear palsy, poisoning by sulfur gas exposure, chlorine gas exposure and nerve gas exposure. The drug candidate is administered subcutaneously. It is a small molecule catalytic antioxidant targeting NADPH (NOx4).
It was also under development for the treatment of prostate cancer, amyotrophic lateral sclerosis, non-small cell lung cancer and mesothelioma.
New Amsterdam Sciences overview
New Amsterdam Sciences (NAS) is a clinical-stage biotechnology company which develops candidate anti-oxidant and anti-fibrotic compounds for the treatment of persistent inflammatory conditions such as pulmonary fibrosis and CNS disorders. Its pipeline products include NAS150, a superoxide dismutase (SOD) mimetic that reduce oxidative stress for indications such as progressive supranuclear palsy (PSP), idiopathic pulmonary fibrosis, and radiation-induced lung injury; NAS114 for Parkinson’s disease and epilepsy; NAS415 targeting cystic fibrosis; NAS911, a synthetic 11-amino acid peptide of Substance P (SP) that activates neurokinin (NK)-1 receptor targeting idiopathic pulmonary fibrosis (IPF). The company has partnerships with St. Jude Children’s Research Hospital, University of Rochester Medical Center and University of Kansas Medical Center. NAS is headquartered in Scottsdale, Arizona, the US.
For a complete picture of NAS-150’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
Smarter leaders trust GlobalData
Premium Insights Likelihood of Approval and Phase Transition Success Rate Model - NAS-150 in Progressive Supranuclear Palsy
Premium Insights
The gold standard of business intelligence.
